AbbVie seeks EU nod for subcutaneous Skyrizi in Crohn's disease
- Posted on August 28, 2026
- By Bing News
- 0 Views
- 1 min read
In brief
Generating AI summary…
AbbVie seeks EU nod for subcutaneous Skyrizi in Crohn's disease
AbbVie ABBV announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking approval for its blockbuster immunology drug, Skyrizi (risankizumab), for subcutaneous (SC) induction in adult patients with moderately to severely active Crohn's disease (CD). If approved, adult patients with CD in the EU would have an additional SC induction option of Skyrizi alongside the currently approved intravenous (IV)...
